TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26337626
Drug: Progressive multicomponent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive multicomponent intervention (home-based progressive strength, mobility and activities of daily living training)
Study: 19665606
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 clade 1 subunit vaccine
Study: 19665606
Drug: Plain H5N1
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain H5N1 clade 1 subunit vaccine
Study: 17659909
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (2.0 g protein/kg/day)
Study: 17659909
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.5 g protein/kg/day)
Study: 27703067
Drug: Fibrin gel
Normalized name: thrombin
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin gel
Study: 11895913
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5‐fluorouracil (MF)
Study: 10362116
Drug: Melatonin 40
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 40 mg orally for 21 days
Study: 1788754
Drug: Intravenous PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGE1
Study: 1788754
Drug: Intravenous Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Pentoxifylline
Study: 7259364
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic glucose solution)
Study: 31653513
Drug: anti-PCSK9 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PCSK9 monoclonal antibodies (mAbs) alirocumab or evolocumab
Study: 30152298
Drug: Supported 6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported 6-week online intervention based on cognitive behavioural therapy (iCBT)
Study: 25698197
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 μg/kg) administered intravenously during re-warming
Study: 25698197
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline administered intravenously during re-warming)
Study: 18223031
Drug: Rosiglitazone vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone vs Metformin
Study: 10817086
Drug: Cerivastatin 0.3
Normalized name: cerivastatin 0.3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.3 mg
Study: 9737646
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg
Study: 3071952
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus Anandron (300 mg daily)
Study: 29293181
Drug: Intermittent boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent boluses (21 mL/3 h) of 0.2% ropivacaine
Study: 29293181
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (7 mL/h) of 0.2% ropivacaine
Study: 27669730
Drug: ATG+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG+G-CSF
Study: 24070164
Drug: FOLFOX-4 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 regimen (oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU bolus 400 mg/m², 5-FU infusion 600 mg/m²) administered every 2 weeks for two consecutive days.
Study: 19940093
Drug: 3% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% carbohydrate solution with electrolytes
Study: 19940093
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate solution with electrolytes
Study: 19940093
Drug: 12% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% carbohydrate solution with electrolytes
Study: 16253026
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication therapy
Study: 12020181
Drug: Symptom-triggered treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered treatment with oxazepam
Study: 12020181
Drug: Fixed-schedule treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule treatment with oxazepam
Study: 10219832
Drug: Plastic flakes
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plastic flakes (24 g/day)
Study: 10219832
Drug: Small granules
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small granules (24 g/day)
Study: 2145400
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg IV)
Study: 7206593
Drug: diatrizoate with
Approvals — FDA: no, EMA: no, PMDA: no
Description: diatrizoate with added calcium (11.3 mmol/l)
Study: 27789095
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg twice a day (BID) for 4 weeks
Study: 27789095
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Lovenox in conjunction with pneumatic compression devices (from a recent randomized controlled trial)
Study: 11180024
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily
Study: 11417442
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg once daily
Study: 11180024
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg once daily
Study: 9924266
Drug: Lutein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplementation (15 mg/d as mixed ester forms) for 4 months
Study: 30224533
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin 10 mg/kg (450 mg)
Study: 30224533
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin 20 mg/kg (900 mg)
Study: 30224533
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin 30 mg/kg (1,350 mg)
Study: 30224533
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin (all doses)
Study: 30224533
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of rifampin
Study: 21586501
Drug: Social Effectiveness
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Effectiveness Therapy for Children (SET‐C)
Study: 8694013
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement containing phosphate and vitamins
Study: 1304482
Drug: Single carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single carboplatin (cp) at the dose of 260‐410 mg/m2
Study: 1304482
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of carboplatin (cp) at a dose of 180‐350 mg/m2 plus adriamycin and cyclophosphamide
Study: 1304482
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of carboplatin (cp) plus adriamycin and cyclophosphamide
Study: 3534333
Drug: Lovastatin (mevinolin)
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin (mevinolin) 40 mg twice a day
Study: 30172864
Drug: Hyoscine Butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine Butylbromide (HB) administered once DR occurs (Group 1)
Study: 25348244
Drug: APAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP treatment
Study: 19664296
Drug: Trehalose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose (75 g carbohydrate equivalents)
Study: 19664296
Drug: Glucose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (75 g carbohydrate equivalents)
Study: 15020035
Drug: Experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agent (exact agent not specified)
Study: 11686541
Drug: Aldosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone (0.5 mg) during normoxia (FiO2=0.21)
Study: 17663307
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin receptor antagonists
Study: 11706714
Drug: Phlogenzym (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlogenzym (3 times 3 tablets for the first three days, then 3 times 2 tablets)
Study: 11706714
Drug: Standard antioedematous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antioedematous drugs based on aescin (control group)
Study: 9706373
Drug: New slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New slow-release tablet formulation (Pindac)
Study: 9706373
Drug: Standard slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard slow-release capsule formulation
Study: 27627817
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg aspirin before surgery and 100 mg daily for up to 30 days after surgery
Study: 27627817
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before surgery and placebo daily for up to 30 days after surgery
Study: 27627817
Drug: Aspirin (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (pooled analysis)
Study: 24478190
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mg iodine pro ml
Study: 24478190
Drug: Ioversol 320
Normalized name: IOVERSOL 320MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioversol 320 mg iodine pro ml
Study: 20401355
Drug: Glutamate (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (1.0 mol/L) injection
Study: 20401355
Drug: Co-injection of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-injection of NMDA antagonist ketamine (10 mmol/L)
Study: 11711256
Drug: Azithromycin oral
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin oral suspension, 10 mg/kg once daily for 3 days
Study: 3980239
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program for family members including counseling and a booklet on supporting medication compliance, appointment keeping, diet, and weight control.
Study: 27958622
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous ampicillin every 6 hours
Study: 27958622
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of intravenous ampicillin every 6 hours
Study: 8394538
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy
Study: 20207497
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation (79.2 GyE)
Study: 17261244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three drugs from two different classes (2 nucleosides or nucleotide analogs (NRTI) plus 1 non‐nucleoside (NNRTI) or 1 boosted protease inhibitor (PI/r))
Study: 17261244
Drug: Delay of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay of therapy in patients with CD4+ counts of > 350 cells/microl
Study: 17261244
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to therapy
Study: 17261244
Drug: Individualized approach
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized approach to therapy
Study: 9491833
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal oestradiol (50 microg daily)
Study: 9491833
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (50 microg daily) and medroxyprogesterone acetate (10 mg daily for the first 12 days of each month)
Study: 7942414
Drug: Anticoagulant drugs
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant drugs
Study: 31989155
Drug: High-dose DCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DCB (In.Pact™)
Study: 31989155
Drug: Low-dose DCB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DCB (Ranger™)
Study: 25640628
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus standard-dose cisplatin and 5-fluorouracil (SDPF) chemotherapy (arm A)
Study: 25640628
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy (arm B)
Study: 15956927
Drug: Adenosine (Ado)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (Ado) infusion over 10 min at systemic pressure during IAC bypass surgery
Study: 15956927
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion over 10 min at systemic pressure during IAC bypass surgery
Study: 11172846
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg esterified estrogen
Study: 21077506
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen
Study: 9644978
Drug: Doxazosin 4-8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4-8 mg (mean 5.7 mg)
Study: 27856335
Drug: Active grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active grape formulation
Study: 27856335
Drug: Placebo (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (formulation free of polyphenols)
Study: 17122241
Drug: Single-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection technique (Group S) with 25 mL of mepivacaine 1%
Study: 17122241
Drug: Double-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection technique (Group D) with 12.5 mL of mepivacaine 1% injected twice
Study: 9692413
Drug: Controlled-release low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release low dose aspirin (75 mg)
Study: 9692413
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation aspirin (75 mg)
Study: 7837399
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose epidural fentanyl (HEF)
Study: 9084455
Drug: 10 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 dose of pegylated-liposomal doxorubicin for the first cycle, followed by 20 mg/m2 every 3 weeks
Study: 9084455
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 dose of pegylated-liposomal doxorubicin every 3 weeks
Study: 31543516
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake with Ca:Mg ratio between 1.7 and 2.5
Study: 26355169
Drug: Calcium‐incorporated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐incorporated implants (Xpeed)
Study: 23342969
Drug: Brassica rapa
Normalized name: BRASSICA RAPA POLLEN
DrugBank: Brassica rapa pollen (DB10942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brassica rapa ethanol extract (BREE) 2 g/day
Study: 21936892
Drug: Placebo (starch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch, 2 g/day)
Study: 18977811
Drug: Oral tizanidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tizanidine (TZD)
Study: 12370455
Drug: Tricyclic Antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic Antidepressants (TCA)
Study: 10187881
Drug: Glucose potassium
Normalized name: glucose / potassium chloride
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose potassium insulin (GKI) infusion at 100 mL/h consisting of 16 U human soluble insulin and 20 mmol potassium chloride in 500 mL 10% glucose
Study: 1854670
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Study: 1854670
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 8)
Study: 1854670
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Study: 29390054
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan hydrochloride and docetaxel
Study: 27349715
Drug: Local liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local liposomal bupivacaine (LB) - 20 mL of bupivacaine/10 mL of saline solution
Study: 23899039
Drug: Six-monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six-monthly monitoring
Study: 20459820
Drug: Three-monthly monitoring
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly monitoring (Control)
Study: 18250253
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h)
Study: 18250253
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with lamotrigine (300 mg)
Study: 9875583
Drug: Isoniazid (H)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (H) 6 months, twice a week
Study: 9875583
Drug: Rifampicin (R)
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (R) plus Pyrazinamide (Z) 3 months, twice a week
Study: 1095306
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg diftalone daily for 2 weeks
Study: 71973
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin daily for 2 weeks
Study: 31888740
Drug: n‐3 PUFA‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA‐enriched medium/long‐chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG)
Study: 20497239
Drug: DHEA 25
Normalized name: GNP DHEA 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 25 mg/day p.o. for 6 months
Study: 20497239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormone replacement)
Study: 18257399
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy and radiation therapy
Study: 18257399
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy and surgery
Study: 10714612
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac‐Na effervescent (fast-release NSAID)
Study: 10714612
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac‐Na effervescent (fast-release NSAID)
Study: 10714612
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac tablets (control)
Study: 8854192
Drug: Protocol 5:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 5: biphasic injection of 100 mL of iohexol 300 (g/100 mL) at a flow rate of 1.5 mL/second followed by 25 mL at 2 mL/second; total iodine load = 37.5 g, with a scan delay of 70 seconds
Study: 30577864
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF) treatment (5 μg/kg/day for 5 days followed by every 3 days) in patients with partial response (PR) to corticosteroids.
Study: 30577864
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF) treatment in patients with null response (NR) to corticosteroids.
Study: 30577864
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/day for 1 week) followed by 28 days of treatment and tapering for an additional 2 weeks in patients with partial response (PR).
Study: 18301879
Drug: Pre-operative heparin
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative heparin infusion
Study: 12079501
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (administered by intravenous infusion every two weeks for 6 months)
Study: 10418756
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g once daily (CTX)
Study: 7740639
Drug: Citalopram (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10-40 mg/day) for three and six weeks
Study: 7740639
Drug: Citalopram (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10-40 mg/day)
Study: 27697302
Drug: EP-1300 polyepitope
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-1300 polyepitope DNA vaccine administered via electroporation